



**FIRST PATIENT SCREENED FOR THE EUROPEAN PRODUCT CANDIDATE  
ESTELLE® (E4/DRSP) PHASE III CLINICAL STUDY:  
THE PHASE III HAS STARTED IN EUROPE AHEAD OF SCHEDULE**

**Liège, Belgium 30 June 2016** – Mithra announces today that the first patient has been screened for enrolment in the European Phase III clinical trials for its Estetrol-based product candidate Estelle® (E4/DRSP). The screening of this first patient marks the launch of the Estelle® (E4/DRSP) Phase III clinical trial in Europe.

This Phase III has started ahead of the envisaged timing and objectives, as it was planned for H2 2016, as announced in the Prospectus.

**François Fornieri, CEO of Mithra Pharmaceuticals:** *“This represents a significant step in the development of Estelle®, highlighting the work of our dedicated R&D and regulatory affairs teams. We are looking forward to further enrolling patients in Europe, as well as launching this Phase III in the United States.”*

The Phase III clinical program will evaluate the contraceptive efficacy of Estelle® (E4/DRSP) in adult women. The trial launched in Europe/Russia is aimed at enrolling 1550 patients aged from 18 to 50 year. These will receive Estelle® (E4/DRSP) during 12 months.

## **Pictures**

For pictures of François Fornieri, please click here on the following link:

<http://www.mithra.com/en/logo/>

## **For more information, please contact:**

### **Press**

**Julie Dessart**

Chief Communication Officer

+32 4 349 28 22

+32 475 86 41 75

[press@mithra.com](mailto:press@mithra.com)

## Investor Relations

**François Fornieri, CEO**

+32 4 349 28 22

[investorrelations@mithra.com](mailto:investorrelations@mithra.com)

## About Mithra

Mithra Pharmaceuticals SA, founded in 1999 as a spin-off of the University of Liège by Mr. François Fornieri and Prof. dr. Jean-Michel Foidart, is a pharmaceutical company focused on Women's Health. Mithra's mission is to support and assist women at every stage of their life, thereby improving their overall quality of life. As such the Company aims to become a worldwide leader in women's health by developing, manufacturing and commercialising proprietary, innovative and differentiated drugs and complex therapeutical entities in four therapeutic fields of women's health, fertility and contraception, menopause and osteoporosis, vaginal infections and cancers.

Mithra has a total headcount of approximately 85 staff members and is headquartered in Liège, Belgium. Further information can be found at: [www.mithra.com](http://www.mithra.com)

## Important information

*The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the words "believes", "estimates," "anticipates", "expects", "intends", "may", "will", "plans", "continue", "ongoing", "potential", "predict", "project", "target", "seek" or "should", and include statements the Company makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. The Company's actual results may differ materially from those predicted by the forward-looking statements. The Company undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law.*

To subscribe to Mithra's newsletter, visit [investors.mithra.com](http://investors.mithra.com)